• Return to Headlines

Upgrade Alert for Pharmacyclics (PCYC)

By Nick Russo

Pharmacyclics (NASDAQ:PCYC) was upgraded from Neutral to Buy at Nomura today. The stock closed yesterday at $170.21 on volume of 1.0 million shares, below average daily volume of 1.0 million.

In the past 52 weeks, shares of Pharmacyclics have traded between a low of $82.51 and a high of $172.11 and closed yesterday at $170.21, which is 106% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.7% while the 200-day MA has risen 0.6%.

Pharmacyclics, Inc. is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. The Company's products are patented agents derived from its technology platform for designing and synthesizing energy-potentiating drugs.

There is potential upside of 0.2% for shares of Pharmacyclics based on a current price of $170.21 and an average consensus analyst price target of $170.47. The stock should find initial support at its 50-day moving average (MA) of $143.62 and further support at its 200-day MA of $119.94.

SmarTrend recommended that subscribers consider buying shares of Pharmacyclics on January 13th, 2015 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $147.27. Since that recommendation, shares of Pharmacyclics have risen 15.6%. We continue to monitor PCYC for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: analyst upgrades/downgrades pharmacyclics

Ticker(s): PCYC